| Literature DB >> 34943547 |
Achmad Adhipatria Perayabangsa Kartamihardja1,2, Winda Ariyani3, Hirofumi Hanaoka4, Ayako Taketomi-Takahashi1, Noriyuki Koibuchi3, Yoshito Tsushima1,5.
Abstract
Gadolinium deposition in the brain has been observed in areas rich in iron, such as the dentate nucleus of the cerebellum. We investigated the role of Fe2+ in the effect of gadolinium-based contrast agents (GBCA) on thyroid hormone-mediated Purkinje cell dendritogenesis in a cerebellar primary culture. The study comprises the control group, Fe2+ group, GBCA groups (gadopentetate group or gadobutrol group), and GBCA+Fe2+ groups. Immunocytochemistry was performed with an anti-calbindin-28K (anti-CaBP28k) antibody, and the nucleus was stained with 4',6-diamidino-2-phenylindole (DAPI). The number of Purkinje cells and their arborization were evaluated with an analysis of variance with a post-hoc test. The number of Purkinje cells was similar to the control groups among all treated groups. There were no significant differences in dendrite arborization between the Fe2+ group and the control groups. The dendrite arborization was augmented in the gadopentetate and the gadobutrol groups when compared to the control group (p < 0.01, respectively). Fe2+ significantly increased the effect of gadopentetate on dendrite arborization (p < 0.01) but did not increase the effect of gadobutrol. These findings suggested that the chelate thermodynamic stability and Fe2+ may play important roles in attenuating the effect of GBCAs on the thyroid hormone-mediated dendritogenesis of Purkinje cells in in vitro settings.Entities:
Keywords: Gd toxicity; Purkinje cells; gadolinium (Gd); gadolinium-based contrast agent (GBCA); neuron morphogenesis; transmetallation
Year: 2021 PMID: 34943547 PMCID: PMC8699861 DOI: 10.3390/diagnostics11122310
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Total Purkinje cell number of the (A) gadopentetate group and (B) gadobutrol group. There were no differences in cell number among all treated groups when compared to the control group. (C) Representative images of the cells at low magnification (10×). ns: not significant.
Figure 2Changes in the relative dendritic area of the Purkinje cells post incubation with gadopentetate with/without Fe2+. (A) Gadopentetate significantly increased Purkinje cells’ dendrite arborization compared to the control group, particularly at 100 nM. (B) Fe2+ attenuated the effect of gadopentetate on the dendrite arborization. (C) The relative dendritic area of Fe2+ + gadopentetate-treated cells was significantly higher than for gadopentetate-treated cells. (D) Representative photomicrograph of gadopentetate-treated Purkinje cells. ** p < 0.01 and * p < 0.05 indicate a statistical significance by Tukey’s HSD post-hoc test compared to the control, unless indicated with a significance bar. ns: not significant.
Figure 3Changes in the relative dendritic area of the Purkinje cells post incubation with gadobutrol with/without Fe2+. (A) Representative photomicrograph of gadobutrol-treated Purkinje cells. (B) Incubation with gadobutrol significantly increased the Purkinje cell dendrite arborization compared to the control group, especially at 10 nM. (C) Fe2+ did not increase the effect of gadobutrol on dendrite arborization. (D) The relative dendritic area of Fe2+ + gadobutrol-treated cells was similar to that of the gadobutrol-treated cells. ** p < 0.01 and * p < 0.05 indicate a statistical significance by Tukey’s HSD post-hoc test compared to the control group, unless indicated with a significance bar. ns: not significant.
Characteristics of Magnevist® and Gadovist® [2,32,33].
| Gadopentetate Dimeglumine (Magnevist®) | Gadobutrol (Gadovist®) | |
|---|---|---|
| Chemical Structures | ||
| Molecular weight | 938 g/mol | 604.71 g/mol |
| Ionic charge | divalent ionic | non-ionic |
| Concentration | 0.5 M | 1.0 M |
| Osmolality | 1960 | 1603 |
| Excess ligand | 0.4 mg/mL | - |
| log Ktherm | 22.5 | 21.8 |
| log Kcond | 18.4 | 14.7 |
| Kinetic stability | Low | High |
Figure 4Proposed mechanism of how the concentration ratio between Fe2+ and chelated gadolinium (Gd[L]) contributes to transmetalation. When the Fe2+ concentration is lower than Gd[L] with excess ligand [L]e, Fe2+ will bind primarily with the [L]e before competing with Gd[L]. However, when the Fe2+ concentration is higher than Gd[L], the [L]e may not be sufficient for Fe2+ binding. Consequently, Fe2+ will compete with Gd[L], resulting in Gd3+ being released from its chelate (transmetalation). When transmetalation occurs in vivo, Gd3+ may bind with endogenous molecules such as phosphate or carbonate or may form a macromolecule complex.